NEW YORK (GenomeWeb News) – Ligon Discovery, a protein microarray developer based in Cambridge, Mass., has reeled in $1 million in financing from IncTank Ventures, Ligon Discovery Co-founder Patrick Kleyn confirmed today.

The firm plans to use the venture funding to screen more than 100 proteins that could be used for drugs.

Ligon's small-molecule microarrays (SMMs) technology platform was developed by and licensed from Harvard University and Broad Institute.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.